Enhanced TextPhase 4NCT00846209
Improving Prescription Drug Warning Labels
A Phase 4 study testing Enhanced drug labeling in people with Enhanced Text and Enhanced Text + Icon, run by Northwestern University at 1 site in United States.
Trial summary
Prior studies have documented a high prevalence of patients misunderstanding prescription drug warning labels, placing them at risk for medication error. We sought to evaluate the effectiveness of 'enhanced print' drug warnings to improve patient comprehension beyond a current standard.A three-arm, controlled clinical… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Enhanced Text, Enhanced Text + Icon
- What is being tested?
- Enhanced drug labeling
- How many people
- 500 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2007to Feb 2009
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- > 18 years old
Who cannot join
- cognitive impairment
- vision or hearing impairment
- non-English speaking
- severely ill
Trial locations and contacts
1 site in 1 country.
United States1 site
Northwestern Memorial Faculty Foundation
Chicago, Illinois, 60611
About this study
Prior studies have documented a high prevalence of patients misunderstanding prescription drug warning labels, placing them at risk for medication error.
We sought to evaluate the effectiveness of 'enhanced print' drug warnings to improve patient comprehension beyond a current standard.A three-arm, controlled clinical trial was conducted. Patients were assigned to receive 1) current standard drug warning labels on prescription containers (standard), 2) 'enhanced' drug warnings with text rewritten in plain language (enhanced text), or 3) enhanced language and icons developed with patient feedback (enhanced text + icon).
Read more
Setting: Two academic and two community health primary care clinics in Chicago, IL and Shreveport, LA.
Patients: 500 adult patients consecutively recruited at each clinic. Main Outcome Measure: Rates of correct interpretation of nine drug warning labels as determined by a blinded panel review of patients' verbatim responses.
Read the detailed description
Adult patients attending one of four outpatient primary care clinics were recruited in two distinct cities (Shreveport, Louisiana; Chicago, Illinois). One clinic in each city was a general medicine academic practice; a second clinic was a safety net community health center. Subject recruitment took place between June and August 2007. Patients were considered eligible for the study if they were 18 years of age or older, and ineligible if the clinic nurse or study research assistant identified a patient as having one or more of the following conditions: (1) severely impaired vision; (2) hearing problems; (3) too ill to participate in the survey; 4) non-English speaking. Institutional Review Boards for all locations approved the study. A total of 562 patients were approached in the order they arrived at the clinics and prior to the medical encounter; 530 consented to the study. Thirteen patients were excluded based on self-reported impairments with hearing (n=3) or vision (n=10). Ten patients were excluded due to limited English proficiency, and seven others were excluded based on incomplete information. In all, 500 patients participated in the study; the sample was evenly split across the two study locations (n=250 per city) and practice setting (academic, community; n=125 within each study location). A response rate was determined following the American Association for Public Opinion Research standards, estimating 92.8 percent of approached eligible patients participated in the study.13 Intervention The intervention was the use of 'enhanced' auxiliary prescription drug warning labels, with or without patient-centered icons to support comprehension. Previously, nine of the most commonly-used drug warnings and/or precautions placed directly on prescription medication bottles were revised with patient feedback and pilot tested.12 Specifically, text was rewritten using more clear, concise, and explicit language. The icons supporting comprehension of the text message were altered to more accurately reflect the mental representations patients identified with each warning (see Table 1). Guidelines established by the International Organization for Standardization for the development and testing of universal icons were followed.14 Other design elements were also implemented, including removal of the use of color and optimizing font size for clarity.
Structured Interview A structured "cognitive" interview protocol was developed to assess patient understanding of the drug labels; a process previously used by our research team.1-4,15 After patients consented to the study, a trained research assistant administered the structured interview that included self-report of sociodemographic information (age, gender, race/ethnicity, education, number of prescription medications currently taken daily). Actual prescription pill bottle containers with drug warning labels attached were then shown to all of the patients for review. Once the patient provided their interpretations, the research assistant administered the Rapid Estimate of Adult Literacy in Medicine (REALM), a reading recognition test comprised of 66 health-related words. The REALM is the most commonly used test of patient literacy in medical settings.16 It is highly correlated with standardized reading tests and the Test of Functional Health Literacy in Adults.17, 18 Assignment Nine drug warnings were used in this study. Each warning had three versions (standard, enhanced text, enhanced text + icon) for a combined total of 27 labels under evaluation. Within each label version, warnings were randomly organized into groups of three labels and then placed on the back of prescription bottles. We viewed three warnings on a bottle to be a realistic portrayal of the number of warnings commonly found on pill bottles; many pharmacies allot space for as many as five per bottle (see Figure). In total, nine bottles were created (three bottles per label version).
The initial order of the warnings on the back of the bottle (e.g. first, second, or third position) was also randomly assigned and replicated across all label versions (see Figure). The bottles were then randomly grouped into three sets; every set containing one bottle from each label version and all of the nine warnings (Table 1). Patients thereby were exposed to all of the drug warnings and each label type, only seeing one version of each warning message. Consecutive patients scheduled for medical appointments at each of the clinics that consented to the study were subsequently assigned, in a systematic rotating order, to one of the three regimens to review.
Outcomes Patient attendance to and correct interpretation of the nine prescription drug warnings placed on container vials were evaluated. A trained research assistant at each location would direct patients to the back of one of three prescription vials, and ask "In your own words, what do these mean to you?" The patient's verbatim responses were documented on a separate form. All patient responses to each of nine drug warnings were then independently rated as either correct or incorrect by three general internal medicine attending physicians from three different academic medical centers. If subjects did not attempt to interpret one of the warning labels in their responses, this was coded as 'non-attendance'.
Blinding and Coding Each physician rater was blinded to all patient information and was trained to follow stringent coding guidelines agreed upon previously by the research team. Specifically, correct scores were to be given only if the patient's response included all aspects of the label's message. Responses were given an incorrect score if they were inaccurate, or if they did not contain all aspects of the warning.
Inter-rater reliability between the three physicians coding the patient responses was high (Kappa = 0.87). The 380 responses (8.4%) that received discordant ratings between the three reviewers were sent to an expert panel that included a primary care physician and clinical psychologist and health services researcher with expertise in health literacy for further review. Each panel member, also blinded to patient information, independently reviewed and coded the responses as correct or incorrect. For 86.1 percent (n=327) of the 380 responses, a consensus ruling was achieved among the expert panel for a final ruling on the coding of those responses. For the remaining 53 patient responses, a majority rule was imposed and the rating by a minimum of two panel members was used to determine the scores.
- Conditions
- Enhanced Text, Enhanced Text + Icon
- Being tested
- Enhanced drug labeling
- Keywords
- prescription drug, warnings, health literacy, enhanced language
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Enhanced drug labelingOther
use of clear concise text and icons on drug warning labels
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2009 (estimated)
- Study startJun 2007
- Primary completionAug 2008
- Study completionFeb 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Enhanced TextStudies of the same condition, open and under way.
- More trials run by Northwestern UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 500 participants (actual)
Sponsor and investigators
- Lead sponsor
- Northwestern University
- Sponsor type
- University, hospital or other
- Collaborators
- Louisiana State University Health Sciences Center Shreveport, Emory University
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00846209
- Sponsor's protocol ID
- 0923-010
- Status last verified
- Nov 2023
- First submitted
- 13 Feb 2009
- Last updated
- 14 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving Prescription Drug Warning Labels
- ClinicalTrials.gov ID
- NCT00846209
- Acronym / sponsor ID
- 0923-010
- Conditions
- Enhanced Text, Enhanced Text + Icon
- Keywords
- prescription drug, warnings, health literacy, enhanced language
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 500 participants (actual)
- Lead sponsor
- Northwestern UniversityUniversity, hospital or other
- Collaborators
- Louisiana State University Health Sciences Center Shreveport, Emory University
- Study start
- Jun 2007
- Primary completion
- Aug 2008 (actual)
- Study completion
- Feb 2009 (actual)
- First posted
- 18 Feb 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prior studies have documented a high prevalence of patients misunderstanding prescription drug warning labels, placing them at risk for medication error.
We sought to evaluate the effectiveness of 'enhanced print' drug warnings to improve patient comprehension beyond a current standard.A three-arm, controlled clinical trial was conducted. Patients were assigned to receive 1) current standard drug warning labels on prescription containers (standard), 2) 'enhanced' drug warnings with text rewritten in plain language (enhanced text), or 3) enhanced language and icons developed with patient feedback (enhanced text + icon).
Setting: Two academic and two community health primary care clinics in Chicago, IL and Shreveport, LA.
Patients: 500 adult patients consecutively recruited at each clinic. Main Outcome Measure: Rates of correct interpretation of nine drug warning labels as determined by a blinded panel review of patients' verbatim responses.
Detailed description
Adult patients attending one of four outpatient primary care clinics were recruited in two distinct cities (Shreveport, Louisiana; Chicago, Illinois). One clinic in each city was a general medicine academic practice; a second clinic was a safety net community health center. Subject recruitment took place between June and August 2007. Patients were considered eligible for the study if they were 18 years of age or older, and ineligible if the clinic nurse or study research assistant identified a patient as having one or more of the following conditions: (1) severely impaired vision; (2) hearing problems; (3) too ill to participate in the survey; 4) non-English speaking. Institutional Review Boards for all locations approved the study. A total of 562 patients were approached in the order they arrived at the clinics and prior to the medical encounter; 530 consented to the study. Thirteen patients were excluded based on self-reported impairments with hearing (n=3) or vision (n=10). Ten patients were excluded due to limited English proficiency, and seven others were excluded based on incomplete information. In all, 500 patients participated in the study; the sample was evenly split across the two study locations (n=250 per city) and practice setting (academic, community; n=125 within each study location). A response rate was determined following the American Association for Public Opinion Research standards, estimating 92.8 percent of approached eligible patients participated in the study.13 Intervention The intervention was the use of 'enhanced' auxiliary prescription drug warning labels, with or without patient-centered icons to support comprehension. Previously, nine of the most commonly-used drug warnings and/or precautions placed directly on prescription medication bottles were revised with patient feedback and pilot tested.12 Specifically, text was rewritten using more clear, concise, and explicit language. The icons supporting comprehension of the text message were altered to more accurately reflect the mental representations patients identified with each warning (see Table 1). Guidelines established by the International Organization for Standardization for the development and testing of universal icons were followed.14 Other design elements were also implemented, including removal of the use of color and optimizing font size for clarity.
Structured Interview A structured "cognitive" interview protocol was developed to assess patient understanding of the drug labels; a process previously used by our research team.1-4,15 After patients consented to the study, a trained research assistant administered the structured interview that included self-report of sociodemographic information (age, gender, race/ethnicity, education, number of prescription medications currently taken daily). Actual prescription pill bottle containers with drug warning labels attached were then shown to all of the patients for review. Once the patient provided their interpretations, the research assistant administered the Rapid Estimate of Adult Literacy in Medicine (REALM), a reading recognition test comprised of 66 health-related words. The REALM is the most commonly used test of patient literacy in medical settings.16 It is highly correlated with standardized reading tests and the Test of Functional Health Literacy in Adults.17, 18 Assignment Nine drug warnings were used in this study. Each warning had three versions (standard, enhanced text, enhanced text + icon) for a combined total of 27 labels under evaluation. Within each label version, warnings were randomly organized into groups of three labels and then placed on the back of prescription bottles. We viewed three warnings on a bottle to be a realistic portrayal of the number of warnings commonly found on pill bottles; many pharmacies allot space for as many as five per bottle (see Figure). In total, nine bottles were created (three bottles per label version).
The initial order of the warnings on the back of the bottle (e.g. first, second, or third position) was also randomly assigned and replicated across all label versions (see Figure). The bottles were then randomly grouped into three sets; every set containing one bottle from each label version and all of the nine warnings (Table 1). Patients thereby were exposed to all of the drug warnings and each label type, only seeing one version of each warning message. Consecutive patients scheduled for medical appointments at each of the clinics that consented to the study were subsequently assigned, in a systematic rotating order, to one of the three regimens to review.
Outcomes Patient attendance to and correct interpretation of the nine prescription drug warnings placed on container vials were evaluated. A trained research assistant at each location would direct patients to the back of one of three prescription vials, and ask "In your own words, what do these mean to you?" The patient's verbatim responses were documented on a separate form. All patient responses to each of nine drug warnings were then independently rated as either correct or incorrect by three general internal medicine attending physicians from three different academic medical centers. If subjects did not attempt to interpret one of the warning labels in their responses, this was coded as 'non-attendance'.
Blinding and Coding Each physician rater was blinded to all patient information and was trained to follow stringent coding guidelines agreed upon previously by the research team. Specifically, correct scores were to be given only if the patient's response included all aspects of the label's message. Responses were given an incorrect score if they were inaccurate, or if they did not contain all aspects of the warning.
Inter-rater reliability between the three physicians coding the patient responses was high (Kappa = 0.87). The 380 responses (8.4%) that received discordant ratings between the three reviewers were sent to an expert panel that included a primary care physician and clinical psychologist and health services researcher with expertise in health literacy for further review. Each panel member, also blinded to patient information, independently reviewed and coded the responses as correct or incorrect. For 86.1 percent (n=327) of the 380 responses, a consensus ruling was achieved among the expert panel for a final ruling on the coding of those responses. For the remaining 53 patient responses, a majority rule was imposed and the rating by a minimum of two panel members was used to determine the scores.
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- > 18 years old
Key exclusion criteria (4 listed)
- cognitive impairment
- vision or hearing impairment
- non-English speaking
- severely ill
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Enhanced drug labelinguse of clear concise text and icons on drug warning labels | Other | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2023.
Related trials for Enhanced Text
Recruiting
Preliminary Effectiveness of Enhanced Text Message + Incentives
Smoking Cessation, Pregnancy
Enrolling by invitation
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Enhanced drug labeling in people with Enhanced Text and Enhanced Text + Icon, run by Northwestern University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2023.